Forever young: the business of longevity drugs

Summary

This Economist Podcasts episode links three evidence problems: the pharmaceutical search for medicines that might improve healthspan, correction of a claim about Afghan nationals and British sexual-offence convictions, and the renewed appeal of miniature craft. The longevity segment frames disease-specific approval, GLP-1 medicines, AI-assisted discovery, patent pressure, and dog trials as routes toward—but not proof of—human life extension. The crime segment shows how a headline 22-fold comparison falls to about seven-fold after reconstructing the population denominator and standardizing for age and sex, while the miniature segment treats compact, controllable worlds as analogue creativity and qualified escapism.

Key Claims

• The FDA does not recognize aging itself as a disease, so biotechnology companies seek approval for recognized age-related conditions and only later test whether a medicine has broader healthspan or longevity effects.
• Novo Nordisk and Eli Lilly present GLP-1 medicines as possible early longevity drugs because their benefits extend across several age-related disease risks, but the available evidence mainly concerns patients with existing conditions rather than life extension in healthy people.
• Patent-cliff pressure increases large-pharma interest in external longevity assets. The source reports a potential $2.75 billion Eli Lilly agreement with Insilico Medicine and a Novartis agreement with BioAge Labs.
• AI may accelerate biological search and candidate design, but ordinary drug development can take 10–15 years and aging outcomes may need another 10–20 years of observation; investment and founder confidence are not clinical proof.
• Dog studies can observe age-related outcomes faster than human studies, but the transferability of a daily metabolism-oriented treatment from older dogs to human aging remains unconfirmed.
• A claim that Afghan nationals were 22 times more likely than British people to be convicted of sexual offences used an Afghan population estimate of 13,000 derived from fewer than 60 survey respondents.
• Reconstructing annual Afghan population denominators and standardizing for age and sex reduced the estimated conviction-rate disparity to roughly seven-fold, without making the remaining association causal.
• Conviction counts do not equal distinct offenders or victimization prevalence; repeat offences, identification differences, underreporting, social conditions, data cleaning, and self-reported nationality all constrain interpretation.
• Miniature-making is growing as a detailed, cross-generational analogue hobby whose compact physical scale supports craft, collection, social exchange, imaginative world-building, and a sense of manageable control.

Key Quotes

No reliable verbatim quotations are available in the supplied markdown. It is a structured episode summary rather than a transcript, so this ingest does not reconstruct quotations.

Connections

• Economist Podcasts - publisher and episode context.
• Longevity Drug Regulatory Pathway - disease-first approval and long evidence horizon for longevity medicines.
• GLP-1 Agonists, Novo Nordisk, and Eli Lilly - metabolic-drug category and companies used as the leading commercial example.
• Insilico Medicine, AI Clinical Validation In Drug Discovery, and Multinational Pharma Patent-Cliff Anxiety - AI discovery, external deal-making, and clinical-proof boundaries.
• Crime Statistics Comparability and Demographic Standardization of Crime Rates - denominator, population-composition, geography, and measurement constraints on crime-rate comparisons.
• Afghanistan and United Kingdom - nationality and jurisdiction used in the contested conviction-rate comparison.
• Miniature World-Building Escapism - analogue craft, spatial compression, and controllable-world interpretation.

Contradictions

• The episode rejects the reported 22-fold Afghan-to-British sexual-offence conviction comparison as dependent on an unstable population estimate; its reconstructed and age-sex-standardized estimate is roughly seven-fold.
• The seven-fold estimate is not treated as a nationality effect. Convictions rather than unique offenders, possible identification differences, underreporting, social conditions, demographic composition, and inconsistent nationality fields prevent a simple causal interpretation.
• GLP-1 benefits across several diseases do not establish slower biological aging or longer life in healthy people, and animal longevity signals do not establish human efficacy.
• Miniature sales growth and convention attendance support a revival claim but do not establish the size, durability, or causes of the broader market.